Objective: Approximately 25 million individuals older than age 15 identify as transgender, representing about 0.3-0.9% of the world's population. The aim of this paper is to identify and describe important medical and social considerations facing transgender persons with epilepsy. Methods: We performed literature searches on the following terms: transgender AND epilepsy, transgender AND neurology, gender dysphoria AND epilepsy, gender dysphoria AND neurology. We also performed literature searches for common feminizing or masculinizing treatment regimens, and searched for interactions of those treatment regimens with antiepileptic drugs (AEDs) and with seizures. Results: There are multiple bidirectional interactions between AEDs and the commonly used treatments for aligning external sex characteristics with identified gender. The scope of the transgender population with epilepsy remains to be elucidated. Significance: Transgender patients with epilepsy face significant social and medical challenges. Interactions between medical gender-affirming treatments and AEDs are common, and management must depend on knowledge of these interactions to provide appropriate treatment. KEY WORDS: Gender identity, Seizures, Antiepileptic drugs, Male-to-female, Female-to-male.
With several recent high-profile lawsuits involving transgender rights, there has been an increase in awareness of transgender people and the specific challenges faced by this community.
Transgender people experience a discordance between the gender with which they identify and the biologic sex assigned to them at birth. 1 Current estimates indicate that approximately 0.3-0.9% of people are transgender, yielding a worldwide estimated population of 25 million transgender individuals ages 15 and older. 1, 2 Although numbers of transgender people are relatively small, health disparities and many indicators of poor health outcomes are elevated in transgender individuals. 2 Rates of discrimination, abuse, and poor social support structures are much higher in transgender persons, 1 particularly in transgender persons of color.
In addition to medical treatment designed to address biologic sex characteristics, transgender people have unique health care needs including care related to reproductive health (such as egg or sperm storage), and awareness and treatment for diseases associated with birth sex (such as cervical or ovarian cancer in a transgender man). 1 Rates of HIV prevalence are much higher in transgender individuals than in the general population, with prevalence reported to be as high as 12-16%. 3, 4 Epidemiologic studies of neurologic conditions in transgender individuals are rare. One retrospective cohort using English national Hospital Episode Statistics and mortality data of transgender people and multiple sclerosis found a strong association with multiple sclerosis in transwomen (male-to-female), with an adjusted rate ratio of 6.63 (95% confidence interval [95% CI] 1.81-17.01, p = 0.0002) compared to non-transgendered men, suggesting possible effects of exogenous hormones. There was no increased rate of multiple sclerosis in transmen (female-to-male) compared to non-transgendered women. 5 Currently, there are no epidemiologic studies of epilepsy in transgender persons. As there are approximately 50 million people with epilepsy worldwide, 6 if the prevalence of the transgendered population holds for persons with epilepsy, there would be approximately 150,000-450,000 transgendered persons with epilepsy worldwide.
Epilepsy-Specific Considerations
Hormone use "Gender-affirming health care" refers to treatment dedicated to matching an individual's external primary or secondary sex characteristics with their identified gender. Some transgender people may transition to their identified gender socially only, without seeking medical care. Transgender adolescents may undergo treatment with gonadotropin-releasing hormone (GnRH) analogs to suppress biologic puberty. 1, 7 Older transgender individuals may seek feminizing or masculinizing hormones, or gender-reassignment surgery. 1 The interaction of antiepileptic drugs (AEDs) with hormonal treatment must be considered when caring for transgender patients (Table 1) .
Transwomen (male-to-female [MTF] transgender persons)
Typical treatment for transwomen comprises GnRH analog-assisted pubertal suppression (if started in adolescence), starting with the onset of early puberty. However, GnRH analogs are expensive and may not be covered by insurance; an alternative approach is treatment with a progestin (such as depot medroxyprogesterone) to suppress peripheral androgen and gonadotropin secretion. This treatment is continued during treatment with cross-sex steroids, which leads to induced female puberty. Typical treatment is with oral 17-b-estradiol, starting at 5 ug/kg per day and increasing up to an adult dose of 2 mg/day 7 ( Table 2 ). Adults seeking treatment use an antiandrogen to reduce testosterone levels prior to sex reassignment surgery, in conjunction with an estrogen. Spironolactone is commonly used in the United States for its testosterone-suppressing properties, and cyproterone acetate is used commonly in Europe. Estrogen may be administered orally or transdermally, and serum levels checked for a target range of <200 pg/ml (although synthetic estrogens or conjugated estrogens cannot be monitored) 7 (Table 2 ). Long-term treatment with androgen deprivation and estrogen therapy has been linked to increases in visceral fat and triglycerides, as well as blood pressure and insulin resistance. Thus far, long-term studies (up to 18 years) have not shown an increase in cardiovascular-related deaths, except for transwomen continuing to use ethinyl estradiol rather than other preparations of estrogen. 8 No increased cancer rates have been observed.
Hormone interactions with AEDs and effect of hormones on seizure control
The interactions of AEDs with female sex hormones are known from studies on contraception 9 and hormone Key Points • Transgender persons make up 0.3-0.9% of the world's population; no epidemiologic studies exist on the number of transgender patients with epilepsy
• Enzyme-inducing AEDs, in particular, may interact with the hormones used for gender-affirming treatment
• Depression and HIV are relatively common comorbidities in transgender patients replacement therapy, 10 and must be considered when managing epilepsy in the transgendered patient (Table 1) .
Enzyme-inducing AEDs (such as phenytoin, phenobarbital, and carbamazepine; EI-AEDs) increase the glucuronidation and hepatic metabolism of estradiol 11 and subsequently lower the effective systemic dose of estrogen (Table 1) . EI-AEDs can also increase blood levels of sexual hormone binding globulin (SHBG), lowering the active free fraction of estrogen and progesterone, 12 which could lead to a reversal of the feminizing characteristics in transwomen. Noninducing agents could be tried as first-line AEDs in transgender women to avoid this interaction. When inducing agents are necessary, the doses of feminizing hormones may need to be increased, bearing in mind the risk of thromboembolism (particularly if a patient has other risk factors such as smoking or age >40).
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Both lamotrigine and estrogen are metabolized via glucuronidation, 9 and estrogen-containing compounds increase the metabolism of lamotrigine (Table 1) . Therefore, when a patient taking lamotrigine starts or increases the dose of an estrogen-containing preparation, the lamotrigine level must be monitored and the dose adjusted. 11 Estrogen has proconvulsant properties in some patients with epilepsy, vividly demonstrated in 1959 by Logothetis et al., 14 when intravenous infusion of estrogen increased epileptic spikes and sharp waves in 11 of 16 women with epilepsy. Therefore, when transwomen with epilepsy begin treatment with estrogen, an exacerbation of seizure activity is possible, and the patient may need medication adjustment. Although natural progesterone is a neurosteroid 15 and has anticonvulsant properties (through the progesterone metabolite, allopregnanolone), 16 the synthetic medroxyprogesterone most commonly used for gender-affirming treatment is not metabolized to allopregnanolone, and does not offer the same protection.
Transmen (female-to-male [FTM] transgender persons)
Typical treatment for transwomen also uses GnRH analog-assisted pubertal suppression (if started in adolescence), starting with the onset of early puberty. Depot medroxyprogesterone is a less expensive alternative approach for transmen also, used to suppress ovulation and progesterone. Male puberty is then induced with intramuscular testosterone, 25 mg/m 2 every 2 weeks increasing to 100 mg/m 2 every 2 weeks 7 ( Table 2) . Adults seeking treatment may use transdermal or parenteral testosterone, with target serum testosterone levels in the 320-1,000 ng/dl range. If menstruation does not stop with testosterone alone, a progestin (i.e., depot medroxyprogesterone) may be used to stop menses and lower estrogen levels 7 (Table 2 ). There are no reports of increased cardiovascular mortality or increased cancer incidence in transmen using testosterone, although transmen who have not had breast removal and hysterectomy-oophorectomy should have monitoring for estrogen-sensitive cancers, because exogenous testosterone is partially metabolized to estradiol. 8 Intracranial hypertension has been reported as a rare side effect of testosterone therapy. 17 Hormone interactions with AEDs and effect of hormones on seizure control EI-AEDs increase the level of SHBG in the blood, thereby decreasing active free testosterone 12, 18 (Table 1) . In some patients, this effect has significant clinical repercussions over time, and may lead to decreased libido and erectile dysfunction. 12, 19 Total serum testosterone levels may be low 19 or may not change, and therefore serum monitoring of testosterone levels for testosterone dosing should be performed, measuring free levels in transmen who take an EI-AED. Although levetiracetam can affect sperm parameters, testosterone levels are not lowered and may be increased. 20, 21 With the cessation of menstruation, transmen who had catamenial exacerbations of seizure frequency may experience an improvement in seizure control. Testosterone and androgens have primarily anticonvulsant effects; however, because testosterone is metabolized to 17-b-estradiol (with proconvulsant activity), the effects are more mixed. Other testosterone metabolites-androstanediol and dihydrotestosterone-are anticonvulsant. 22 
Comorbidities

Depression and psychiatric comorbidities
Depression and anxiety are common in transgender individuals as well as in patients with epilepsy. Estimates of depression in transgendered persons range from 31 to 64%, significantly higher than in the general population.
2 A national study in Australia found that 56% of transgender individuals have been diagnosed with depression (four times higher than in the general population), and 38% have been diagnosed with anxiety. 1 Suicide is a large risk for this population, and one U.S. study revealed that 41% of transgender respondents had attempted suicide (a rate over 25 times that of the general population). 1 Already marginalized, the social stigma associated with epilepsy in some areas of the world can only be exacerbated by the stigma against transgender persons. No current studies exist on the rates of stigma, depression, and anxiety in the transgender community with epilepsy.
Use of antidepressant medications
The epileptologist must carefully evaluate patients for depression and anxiety, and may wish to avoid medications associated with detrimental mood side effects such as levetiracetam or perampanel if depression is a comorbidity. Most selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are safe in persons with epilepsy, but the epileptologist should coordinate with a treating psychiatrist and recommend that antidepressants that lower the seizure threshold (such as bupropion) be avoided. 23 If levetiracetam is otherwise desirable in a patient with depression or anxiety, supplementation with vitamin B6 (pyridoxine) has been observed to lower rates of agitation and anxiety in some patients, and may be beneficial. 24 EI-AEDs reduce the levels of SSRIs, some SNRIs, bupropion, and trazodone. 25 SSRIs inhibit cytochrome P450 (CYP)2D6 in the liver, which can lead to increased levels of some AEDs 25 ; toxic levels of carbamazepine, phenytoin, and valproate have been reported after initiation of fluoxetine (which also inhibits CYP1A2 and CYP2C19). 25, 26 Sertraline inhibits the glucuronidation of lamotrigine, and has rarely been reported to cause toxic levels. 25 Citalopram, escitalopram, and SNRIs have minimal effects on AED levels. 25 The EI-AEDs increase the metabolism of tricyclic antidepressants (TCAs), leading to low levels; conversely, valproate may inhibit the metabolism of TCAs causing toxicity. 27 TCAs may inhibit the metabolism of some hepatically metabolized AEDs. 27 AED levels should be monitored in patients starting treatment with antidepressants.
Human immunodeficiency virus (HIV)
The rate of HIV prevalence is reported to be much higher in transgender individuals than in the general population.
3 A meta-analysis of 22 studies of HIV prevalence in transgender women found an average HIV prevalence of 27.7%, 4 with large racial differences: the highest prevalence was in African American transgender women at 56.3%, compared to 16.7% in white and 16.1% in Hispanic transgender women. 4 Fewer studies of HIV prevalence in transgender men exist; a meta-analysis of five studies found a much lower rate, with self-reported prevalence of 0-3%. 4 Some studies have found higher rates of HIV in transgender persons than in other high-risk groups such as partners of patients living with HIV. 4 Transgender individuals may experience a delay in obtaining appropriate care and in achieving viral suppression compared to non-transgender individuals. 28 
Use of antiretroviral (ARV) medications
EI-AEDs may lower the levels of protease inhibitors (PIs) and nonnucleotide reverse transcriptase inhibitors (NNRTIs), which are metabolized by the CYP system. When possible, phenytoin, phenobarbital, primidone, and carbamazepine should be avoided in patients on PIs and NNRTIs 29 ; if used, patients should be monitored for ARV treatment failure. 30 Valproate, as an enzyme inhibitor, may increase levels of lopinavir/ritonavir (PI) and zidovudine (NNRTI), and thus adjustments of the ARVs in conjunction with the patient's other physicians may be necessary. 30 The PI combinations atazanavir/ritonavir and lopinavir/ritonavir are known to reduce the concentration of lamotrigine; if used, lamotrigine levels should be monitored and the dose adjusted. 29, 30 Levetiracetam and lacosamide have no known significant interactions with ARVs. 30 
Social Issues
Stigma related to identification as being a transgender person is high and may prevent individuals from accessing health care or from disclosing their condition to their physician. 1 One study showed that 70% of transgender respondents had experienced discrimination in the health care setting on at least one occasion, and that 73% of transgender individuals were reluctant to share their transgender identity with their physician due to fear of discrimination. 31 If transgender patients are not comfortable disclosing their identities to their physicians, the use of exogenous estrogens or testosterone may be unknown to the physician and medications may not be chosen properly. When accessing medical records for continuity of care, the physician must also be aware of any former names used by the patient, which can complicate the process of retrieving information if the name has been changed.
Substance abuse rates are elevated in transgendered persons, perhaps as a response to depression or stress. Illicit drug use was reported by 26.7% of MTFs in a meta-analysis of five studies, and 43.7% reported using alcohol. 4 Substance abuse may increase the risk of poorly controlled epilepsy, as both alcohol and drug use may worsen seizures. Patients with epilepsy and alcohol dependence are at an increased risk of medication noncompliance, increasing the possibility of epilepsy-related death. 32 Some transgender persons cannot or do not seek traditional health care for gender-affirming treatment, and a substantial percentage may purchase hormones from nonmedical sources, 33 such as websites or untrained providers. These products may not have the level of oversight and quality control of medical sources of hormones, and patients may be at risk for seizure exacerbation if using impure or adulterated products. Besides hormone preparations, herbs such as chasteberry, fenugreek, wild yam, fennel, and red clover are marketed as "feminizing" alternatives to hormone therapy, whereas chasteberry, ginseng, and sassafras are marketed as "masculinizing" alternatives. Some of these herbs have inducing or inhibiting effects on the CYP enzymes, and may interact with AEDs. Other supplements such as "Ovary Concentrate" are easily obtainable online. Patients taking these unregulated herbs and supplements may be susceptible to breakthrough seizures in the event of sudden hormone level fluctuations or drug interactions.
Discussion
The commonly used gender-affirming treatments for transgender persons have the potential for interactions with AEDs, as do some antidepressants and ARVs.
Estimates of the transgender population with epilepsy are based on reported numbers of transgender persons and population-based epilepsy prevalence data, as no epidemiologic studies of epilepsy in transgender persons exist. Well-defined population-based studies are needed to estimate the true burden of epilepsy in the transgender population, to assess the prevalence of depression and HIV in transgender patients with epilepsy, and to define other special needs and concerns of this population. In addition, prospective studies of transgender persons with epilepsy beginning treatment with cross-sex hormones have the potential to provide valuable information about the effects of exogenous sex hormones on seizure control and interactions with AEDs.
Conclusion
Transgender persons face significant social stigma and challenges when accessing health care. The physician treating the transgender patient with epilepsy must be aware of the medical regimens used for gender-affirming treatment and the risk of hormonal interaction with AEDs, of the high risk of depression and suicide in transgender patients due to stigma and isolation, and of other social issues facing the patient. Population-based studies are needed to estimate the number of transgender persons with epilepsy and with other neurologic conditions.
Disclosure of Conflict of Interest
Dr. Kaplan receives honoraria from Demos and Wiley for textbooks on EEG, Epilepsy, and Neurology and serves as an expert witness for quantitative EEG. Dr. Johnson reports no financial interests to disclose. We confirm that we have read the Journal's position on issues involved in ethical publishing and affirm that this report is consistent with those guidelines.
